英文论文


文献类型
Article
题名
Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis
作者
Zhang, Lijuan; Huang, Yun; Lin, Yun; Zhang, Aili; Zou, Rong; Xu, Huiying; Wang, Sili
作者单位
[Zhang, Lijuan; Zhang, Aili; Wang, Sili] Fujian Med Univ, Sch Clin Med, Fuzhou, Peoples R China. [Zhang, Lijuan; Huang, Yun; Lin, Yun; Zhang, Aili; Zou, Rong; Xu, Huiying; Wang, Sili] Xiamen Univ, Dept Hematol, Affiliated Hosp 1, Xiamen, Peoples R China.
通讯作者地址
Fujian Med Univ, Sch Clin Med, Fuzhou, Peoples R China.; Xiamen Univ, Dept Hematol, Affiliated Hosp 1, Xiamen, Peoples R China.
Email
wsl1994ok@126.com
ResearchID
ORCID
期刊名称
HEMATOLOGY
出版社
TAYLOR & FRANCIS LTD
ISSN
1024-5332
出版信息
2022-12-31, 27 (1):122-131.
JCR
影响因子
ISBN
基金
会议名称
会议地点
会议开始日期
会议结束日期
关键词
Multiple myeloma; CD56; ASCT; novel drugs; prognosis
摘要
Objectives: Several studies have demonstrated the expression status of CD56 was associated with prognosis in multiple myeloma (MM) patients, the prognostic significance remains controversial. Here, the prognostic value of CD56 is further investigated in MM patients. Methods: We systematically searched the databases including PubMed, EMBASE, Web of Science and the Cochrane Library. The hazard ratios (HRs) with their 95% confidence intervals (CIs) were pooled to evaluate the relationship between CD56 and overall survival (OS) and progress-free survival (PFS). Results: A total of 14 studies covering 1365 patients were included in this meta-analysis. The results revealed that CD56 negativity in MM was associated with poorer OS (HR = 1.83, 95% CI = 1.29-2.60, P = 0.001) and PFS (HR = 1.57, 95% CI = 1.27-1.95, P = 0.000). Subgroup analysis further demonstrated that there was an effect of treatment regimen, detection method, survival analysis, study region and the cut-off value of CD56 on CD56 expression. Discussion and conclusion: The meta-analysis suggested that CD56 negative patients had a poor prognosis for OS in Asian patients and for PFS in non-Asian patients. Novel drugs didn't show a significant improvement or overcome on the adverse prognosis brought by CD56 negativity. For patients undergone autologous stem-cell transplantation (ASCT), the poor prognosis was overcome by the treatment, which shed a light on the prognostic judgment and individualized treatment.
一级学科
Hematology
WOS入藏号
WOS:000746199000001
EI收录号
DOI
10.1080/16078454.2021.2019365
ESI
收录于
SCIE

返回